近日，山东步长制药（603858）股份有限公司（以下简称"步长制药"）控股子公司四川泸州步长生物制 药有限公司（以下简称"泸州步长"）与马来西亚公司MEDISPEC（M）SDN BHD（以下简 称"MEDISPEC"）签署《独家供应协议》，泸州步长授权后者作为其在马来西亚市场的独家代理商。此 举成为步长制药"中药国际化"战略的又一关键落子。 除了走出国门，布局全球市场，近年来，步长制药还不断巩固中药主业优势，积极构建覆盖生物药、中 药、化药的多元化研发管线，并通过高比例分红与回购回馈股东，大力推动公益践行社会责任，正成长 为一个创新引领、回报稳健、担当有力的综合型医药企业。 多元布局支撑长期成长 在推动中药出海的同时，步长制药在创新药研发领域持续深耕，创新药管线多项重点品种迎来关键进 展，为企业长期成长注入动力。 该公司坚持生物药、中药、化药三大领域并进的研发策略。生物药领域进展显著：首个申报上市的1类 新药注射用艾帕依泊汀α正加速冲刺，有望填补国产长效促红细胞生成素（简称EPO）制剂市场空白； 首款生物类似药阿达木单抗注射液已报产在审；另有BC001等多款靶向肿瘤创新药处于临床关键阶段。 中药领域则依托经典 ...

Core Viewpoint - Recently, Buchang Pharma has gained market attention for its innovation in drug development, capital market returns, and commitment to public welfare, showcasing the company's responsibility and dedication in the pharmaceutical industry [1] Innovation Drug Pipeline - Buchang Pharma has made significant advancements in its innovation drug pipeline, covering three major areas: biopharmaceuticals, traditional Chinese medicine, and chemical drugs [2] - The company is accelerating the application of its first Class 1 new drug, Epoetin Alfa, targeting renal anemia and chemotherapy-induced anemia, which could fill a gap in the domestic long-acting EPO market valued at 15 billion [2] - The first biosimilar drug, Adalimumab injection, is under review, targeting multiple autoimmune diseases with substantial market potential [2] - The company is advancing its Class 1 biopharmaceutical BC001 for late-stage gastric cancer and has several targeted cancer drugs in critical clinical development stages [2][4] Traditional Chinese Medicine and Chemical Drug Expansion - In traditional Chinese medicine, the company has completed Phase II clinical trials for its Qi-tonifying granules and is set to start Phase II/III trials for its heart failure treatment granules in May 2025 [4] - In the chemical drug sector, Buchang Pharma has launched 17 new generic drugs in 2023, including products that target a 20 billion market for antiviral drugs and expand its muscle relaxant market [4] - The company has successfully renewed contracts for exclusive products in the 2025 National Medical Insurance Directory, with total sales exceeding 10.3 billion in the first three quarters [4] Shareholder Returns - Buchang Pharma has established a stable return mechanism for investors, with cumulative dividends reaching 7.948 billion and share buybacks totaling 1.744 billion since its listing [5] - In 2025, the company has repurchased 6.6206 million shares, with a total repurchase amount nearing 100 million, demonstrating confidence in its future development [5] Corporate Social Responsibility - Since its inception, Buchang Pharma has adhered to its mission of "creating health for humanity," actively engaging in social responsibility through the "Together, Build China's Heart" initiative for 18 years [6] - The initiative has expanded from congenital heart disease to various medical fields, providing comprehensive medical assistance to over 1 million patients [6] - The company has contributed nearly 33 billion in taxes nationwide, supporting regional economic development [6] Future Outlook - The chairman of Buchang Pharma, Zhao Tao, emphasized the company's commitment to innovation-driven development and social responsibility, aiming to lead industry growth and create greater social value [7]

步长制药（603858.SH）8月15日在投资者互动平台表示，公司的注射用艾帕依泊汀α为治疗用生物制品 Ⅰ类新药，目前国内尚无同类品种批准上市。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司申报的注射性艾帕依泊汀a 和已经上市的同 类型药品占比有什么优势，如果没有显著的优势，怎么在激烈的市场竞争中获胜？ ...